CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

Phase 2

Terminated

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Pomalidomide

First Posted Date: 2008-07-17

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 7

Registration Number: NCT00717522

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
Kootenai Cancer Center, Coeur d'Alene, Idaho, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
Drug: Lenalidomide and low-dose dexamethasone
Drug: Melphalan, Prednisone and Thalidomide

First Posted Date: 2008-06-04

Last Posted Date: 2019-11-20

Lead Sponsor: Celgene

Target Recruit Count: 1623

Registration Number: NCT00689936

Locations: 🇺🇸
Cedar Sinai Medical Center Dept of Medicine, Los Angeles, California, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 282 locations

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Solid Tumors
Lymphoma

First Posted Date: 2008-06-03

Last Posted Date: 2019-09-25

Lead Sponsor: Celgene

Target Recruit Count: 33

Registration Number: NCT00688415

Locations: 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer
Pancreatic Cancer
Lymphoma
Melanoma
Multiple Myeloma

Interventions: Drug: NPI-0052 (marizomib) + vorinostat

First Posted Date: 2008-04-25

Last Posted Date: 2017-11-22

Lead Sponsor: Celgene

Target Recruit Count: 22

Registration Number: NCT00667082

Locations: 🇦🇺
The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇦🇺
Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, Western Australia, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Thalidomide

First Posted Date: 2008-04-14

Last Posted Date: 2019-10-18

Lead Sponsor: Celgene

Target Recruit Count: 400

Registration Number: NCT00657488

Locations: 🇧🇪
Hopital St Joseph, Gilly, Belgium
🇫🇷
Chu D'Angers - Medecine D, Angers, France
🇫🇷
Centre Hospitalier Du Dr Duschene - Hematologie, Boulogne Sur Mer, France

and more 46 locations

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: T-cell Non-Hodgkin's Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2008-04-10

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 54

Registration Number: NCT00655668

Locations: 🇫🇷
CHRU Hôpitaux de Brabois - Hématologie, Vandoeuvre Les Nancy, Rue Morvan Cedex, France
🇫🇷
Hôpital Purpan, Toulouse, France
🇧🇪
Institute Jules Bordet, Bruxelles, Belgium

and more 42 locations

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

Phase 1

Completed

Conditions: MDS
AML
Solid Tumors
Multiple Myeloma
Non-Hodgkin's Lymphoma
Hodgkin's Disease

Interventions: Drug: azacitidine

First Posted Date: 2008-04-04

Last Posted Date: 2019-11-19

Lead Sponsor: Celgene

Target Recruit Count: 31

Registration Number: NCT00652626

Locations: 🇺🇸
Palm Springs Research Institute, Hialeah, Florida, United States
🇺🇸
Sutter East Bay Hospitals, Berkeley, California, United States
🇺🇸
Pharma Resource, East Providence, Rhode Island, United States

and more 8 locations

ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: ABI-009

First Posted Date: 2008-03-13

Last Posted Date: 2019-10-18

Lead Sponsor: Celgene

Target Recruit Count: 27

Registration Number: NCT00635284

Locations: 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: NPI-0052 on Days 1, 4, 8, 11 every 21 days
Drug: NPI-0052 on Days 1, 8, 15 every 28 days
Drug: Dexamethasone

First Posted Date: 2008-03-06

Last Posted Date: 2017-11-22

Lead Sponsor: Celgene

Target Recruit Count: 86

Registration Number: NCT00629473

Locations: 🇦🇺
Mater Adult Hospital, South Brisbane, Queensland, Australia
🇦🇺
The Queen Elizabeth Hospital, Woodville South, South Australia, Australia
🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia

and more 4 locations

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: CC-5013
Drug: Lenalidomide

First Posted Date: 2008-02-25

Last Posted Date: 2019-11-20

Lead Sponsor: Celgene

Target Recruit Count: 330

Registration Number: NCT00622336

Locations: 🇷🇺
Nizhny Novgorod Clinical Hospital n.a.Semashko, Nizhny Novgorod, Russian Federation
🇺🇦
Kharkov Postgraduate Medical Academy Kharkov Regional Clinical, Kharkov, Ukraine
🇺🇦
Institute of Hematology and Transfusiology of the UAMS Department of blood diseases, Kiev, Ukraine

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy